Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms.
Transplantation Tolerance Induction: Cell Therapies and Their Mechanisms.
复制标题
DOI：
10.3389/fimmu.2016.00087
复制
发表时间：
2016
影响因子：
7.3
通讯作者：
Burlingham W
中科院分区：
文献类型：
--
作者：
Scalea JR;Tomita Y;Lindholm CR;Burlingham W
基于细胞的疗法在移植耐受诱导的背景下已得到广泛研究。最成功的方案依赖于同种异体肾移植之前的骨髓输注。然而，尚不清楚骨髓中发现的干细胞是否需要使移植候选者具有免疫耐受性。因此，正在测试间充质干细胞、调节性骨髓细胞、调节性T细胞和其他细胞类型，作为在缺乏供体来源的干细胞的情况下诱导耐受的可能途径。这些细胞类型的早期数据都令人鼓舞。然而，尚未确定能够实现一致耐受性、同时避免不良副作用、并且可适用于人类患者的诱导方案。在这里，我们介绍了各种耐受细胞类型的研究现状以及它们在耐受诱导方案中使用的机制原理。
Cell-based therapies have been studied extensively in the context of transplantation tolerance induction. The most successful protocols have relied on transfusion of bone marrow prior to the transplantation of a renal allograft. However, it is not clear that stem cells found in bone marrow are required in order to render a transplant candidate immunologically tolerant. Accordingly, mesenchymal stem cells, regulatory myeloid cells, T regulatory cells, and other cell types are being tested as possible routes to tolerance induction, in the absence of donor-derived stem cells. Early data with each of these cell types have been encouraging. However, the induction regimen capable of achieving consistent tolerance, while avoiding unwanted sided effects, and which is scalable to the human patient, has yet to be identified. Here, we present the status of investigations of various tolerogenic cell types and the mechanistic rationale for their use in tolerance induction protocols.